Literature DB >> 25455859

Rational design of small molecule inhibitors targeting the Ras GEF, SOS1.

Chris R Evelyn1, Xin Duan1, Jacek Biesiada2, William L Seibel3, Jaroslaw Meller4, Yi Zheng5.   

Abstract

Ras GTPases regulate intracellular signaling involved in cell proliferation. Elevated Ras signaling activity has been associated with human cancers. Ras activation is catalyzed by guanine nucleotide exchange factors (GEFs), of which SOS1 is a major member that transduces receptor tyrosine kinase signaling to Ras. We have developed a rational approach coupling virtual screening with experimental screening in identifying small-molecule inhibitors targeting the catalytic site of SOS1 and SOS1-regulated Ras activity. A lead inhibitor, NSC-658497, was found to bind to SOS1, competitively suppress SOS1-Ras interaction, and dose-dependently inhibit SOS1 GEF activity. Mutagenesis and structure-activity relationship studies map the NSC-658497 site of action to the SOS1 catalytic site, and define the chemical moieties in the inhibitor essential for the activity. NSC-658497 showed dose-dependent efficacy in inhibiting Ras, downstream signaling activities, and associated cell proliferation. These studies establish a proof of principle for rational design of small-molecule inhibitors targeting Ras GEF enzymatic activity.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25455859      PMCID: PMC4272618          DOI: 10.1016/j.chembiol.2014.09.018

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  52 in total

1.  Fluorescent BODIPY-GTP analogs: real-time measurement of nucleotide binding to G proteins.

Authors:  D P McEwen; K R Gee; H C Kang; R R Neubig
Journal:  Anal Biochem       Date:  2001-04-01       Impact factor: 3.365

2.  Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS.

Authors:  S Mariana Margarit; Holger Sondermann; Brian E Hall; Bhushan Nagar; Andre Hoelz; Michelle Pirruccello; Dafna Bar-Sagi; John Kuriyan
Journal:  Cell       Date:  2003-03-07       Impact factor: 41.582

3.  Rictor phosphorylation on the Thr-1135 site does not require mammalian target of rapamycin complex 2.

Authors:  Delphine Boulbes; Chien-Hung Chen; Tattym Shaikenov; Nitin K Agarwal; Timothy R Peterson; Terri A Addona; Hasmik Keshishian; Steven A Carr; Mark A Magnuson; David M Sabatini; Dos D Sarbassov
Journal:  Mol Cancer Res       Date:  2010-05-25       Impact factor: 5.852

4.  Rational design of small molecule inhibitors targeting the Rac GTPase-p67(phox) signaling axis in inflammation.

Authors:  Emily E Bosco; Sachin Kumar; Filippo Marchioni; Jacek Biesiada; Miroslaw Kordos; Kathleen Szczur; Jarek Meller; William Seibel; Ariel Mizrahi; Edgar Pick; Marie-Dominique Filippi; Yi Zheng
Journal:  Chem Biol       Date:  2012-02-24

5.  Regulatory proteins of R-Ras, TC21/R-Ras2, and M-Ras/R-Ras3.

Authors:  Y Ohba; N Mochizuki; S Yamashita; A M Chan; J W Schrader; S Hattori; K Nagashima; M Matsuda
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

6.  Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women.

Authors:  Lori A Field; Brad Love; Brenda Deyarmin; Jeffrey A Hooke; Craig D Shriver; Rachel E Ellsworth
Journal:  Cancer       Date:  2011-07-28       Impact factor: 6.860

7.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

8.  Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function.

Authors:  Harrison J Hocker; Kwang-Jin Cho; Chung-Ying K Chen; Nandini Rambahal; Sreenivasa Rao Sagineedu; Khozirah Shaari; Johnson Stanslas; John F Hancock; Alemayehu A Gorfe
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-04       Impact factor: 11.205

9.  CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling.

Authors:  Chris R Evelyn; Susan M Wade; Qin Wang; Mei Wu; Jorge A Iñiguez-Lluhí; Sofia D Merajver; Richard R Neubig
Journal:  Mol Cancer Ther       Date:  2007-08       Impact factor: 6.261

10.  Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.

Authors:  Olga A Timofeeva; Xueping Zhang; Habtom W Ressom; Rency S Varghese; Bhaskar V S Kallakury; Kan Wang; Youngmi Ji; Amrita Cheema; Mira Jung; Milton L Brown; Johng S Rhim; Anatoly Dritschilo
Journal:  Int J Oncol       Date:  2009-10       Impact factor: 5.650

View more
  19 in total

1.  SOS1 Gain-of-Function Variants in Dilated Cardiomyopathy.

Authors:  Jason R Cowan; Lorien Salyer; Nathan T Wright; Daniel D Kinnamon; Pedro Amaya; Elizabeth Jordan; Michael J Bamshad; Deborah A Nickerson; Ray E Hershberger
Journal:  Circ Genom Precis Med       Date:  2020-06-30

Review 2.  Ras and Rap1: A tale of two GTPases.

Authors:  Seema Shah; Ethan J Brock; Kyungmin Ji; Raymond R Mattingly
Journal:  Semin Cancer Biol       Date:  2018-04-03       Impact factor: 15.707

3.  Screening-based translation of public research encounters painful problems.

Authors:  Jonathan B Baell
Journal:  ACS Med Chem Lett       Date:  2015-02-09       Impact factor: 4.345

4.  Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme.

Authors:  Chris R Evelyn; Jacek Biesiada; Xin Duan; Hong Tang; Xun Shang; Ruben Papoian; William L Seibel; Sandra Nelson; Jaroslaw Meller; Yi Zheng
Journal:  J Biol Chem       Date:  2015-03-30       Impact factor: 5.157

5.  Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs.

Authors:  Özgün Babur; Alexander R Melrose; Jennifer M Cunliffe; John Klimek; Jiaqing Pang; Anna-Liisa I Sepp; Jevgenia Zilberman-Rudenko; Samuel Tassi Yunga; Tony Zheng; Iván Parra-Izquierdo; Jessica Minnier; Owen J T McCarty; Emek Demir; Ashok P Reddy; Phillip A Wilmarth; Larry L David; Joseph E Aslan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

6.  Allosteric KRas4B Can Modulate SOS1 Fast and Slow Ras Activation Cycles.

Authors:  Tsung-Jen Liao; Hyunbum Jang; David Fushman; Ruth Nussinov
Journal:  Biophys J       Date:  2018-07-24       Impact factor: 4.033

7.  Next-generation molecular therapy in lung cancer.

Authors:  Jun Qian; Pierre P Massion
Journal:  Transl Lung Cancer Res       Date:  2018-02

8.  Conformations and binding pockets of HRas and its guanine nucleotide exchange factors complexes in the guanosine triphosphate exchange process.

Authors:  Yuqing Xiong; Juan Zeng; Fei Xia; Qiang Cui; Xianming Deng; Xin Xu
Journal:  J Comput Chem       Date:  2022-03-24       Impact factor: 3.672

9.  A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.

Authors:  Ellen Siebring-van Olst; Maxime Blijlevens; Renee X de Menezes; Ida H van der Meulen-Muileman; Egbert F Smit; Victor W van Beusechem
Journal:  Mol Oncol       Date:  2017-04-11       Impact factor: 6.603

10.  Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia.

Authors:  L M Heltemes-Harris; J D Larson; T K Starr; G K Hubbard; A L Sarver; D A Largaespada; M A Farrar
Journal:  Oncogene       Date:  2015-10-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.